The VEGF-R inhibitor PTK787/ZK222584 (PTK/ZK) also inhibits aromatase: preclinical studies of PTK/ZK in combination with endocrine therapy

被引：0
|
作者：
Banerjee, S. N.
Thornhill, A.
Evans, D. B.
Littlewood-Evans, A. J.
Dowsett, M.
Martin, L-A
机构：
[1] Inst Canc Res, London SW3 6JB, England
[2] Novartis Inst Biomed Res, Basel, Switzerland
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [1] IN VITRO AND IN VIVO STUDIES REVEAL THAT THE VEGF-R INHIBITOR PTK787/ZK222584 IS A COMPETITIVE AROMATASE INHIBITOR
    Banerjee, S. N.
    Zvelebil, M.
    Furet, P.
    Mueller-Vieira, U.
    Dowsett, M.
    Evans, D.
    Martin, L.
    ANNALS OF ONCOLOGY, 2009, 20 : 61 - 61
  • [2] The Vascular Endothelial Growth Factor Receptor Inhibitor PTK787/ZK222584 Inhibits Aromatase
    Banerjee, Susana
    Zvelebil, Marketa
    Furet, Pascal
    Mueller-Vieira, Ursula
    Evans, Dean B.
    Dowsett, Mitch
    Martin, Lesley-Ann
    CANCER RESEARCH, 2009, 69 (11) : 4716 - 4723
  • [3] A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGF-R TK inhibitor in patients with recurrent GBM.
    Friedman, HS
    Yung, WA
    Jackson, E
    Provenzale, J
    Leeds, N
    Conrad, C
    Walker, A
    Henry, A
    Laurent, D
    Dugan, M
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3665S - 3665S
  • [4] Biological Evidence for Dual Antiangiogenic - Antiaromatase Activity of the VEGF-R Inhibitor PTK787/ZK222584.
    Banerjee, S.
    Evans, D. B.
    Littlewood-Evans, A.
    Detre, S.
    Dowsett, M.
    Martin, L-A
    CANCER RESEARCH, 2009, 69 (24) : 811S - 812S
  • [5] A PHASE II TRIAL OF PTK787/ZK 222584 (PTK787) IN RECURRENT OR PROGRESSIVE MENINGIOMA
    Deboer, Rebecca
    Grimm, Sean
    Chandler, James
    Gallot, Lilia
    Kennedy, Shannon
    Burns, Kimberly
    Rice, Laurie
    Cabreza, Czarina
    Muro, Kenji
    Raizer, Jeffrey
    NEURO-ONCOLOGY, 2008, 10 (05) : 824 - 824
  • [6] A PHASE II TRIAL OF PTK787/ZK 222584 (PTK787) IN RECURRENT OR PROGRESSIVE MENINGIOMAS
    Raizer, Jeffrey
    Grimm, Sean
    Chandler, James
    Muro, Kenji
    Rice, Laurie
    McCarthy, Katie
    Mrugala, Maciej
    Johnston, Sandra K.
    Chamberlain, Marc
    NEURO-ONCOLOGY, 2010, 12 : 50 - 50
  • [7] PTK787/ZK222584, an inhibitor of VEGF receptor tyrosine kinases, decreases glioma growth and vascularization
    Goldbrunner, R
    Bendszus, M
    Wood, J
    Kiderlen, M
    Miebach, S
    Tonn, JC
    JOURNAL OF VASCULAR RESEARCH, 2004, 41 (01) : 96 - 96
  • [8] Biomarkers (VEGF, BFGF) for assessing the biological activity of PTK787/ZK222584 (PTK/ZK), a vascular endothelial growth factor (VEGF) receptor inhibitor, in tumours known to overexpress VEGF
    Drevs, J
    Steward, WP
    Dugan, M
    Lee, L
    Laurent, D
    Zirrgiebel, U
    Yung, A
    Rich, J
    Unger, C
    Marme, D
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S78 - S78
  • [9] Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation
    Zips, D
    Krause, M
    Hessel, F
    Westphal, J
    Brüchner, K
    Eicheler, W
    Dörfler, A
    Grenman, R
    Petersen, C
    Haberey, M
    Baumann, M
    ANTICANCER RESEARCH, 2003, 23 (5A) : 3869 - 3876
  • [10] Phase I and pharmacokinetic (PK) study of PTK787/ZK222584 (PTK/ZK) plus capecitabine (cape) in patients (Pts) with advanced cancer
    Schilsky, R. L.
    Geary, D.
    Skoog, L.
    Desai, A.
    Valickas, J.
    Masson, E.
    Laurent, D.
    Pendowski, C.
    Vokes, E.
    Ratain, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345